Drug Trial Radar · NCT07868939
Oral VK2735 for Weight Management in Adults With Type 2 Diabetes Mellitus Phase 3 (SUNRISE 2)
Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
560
Planned (sponsor's estimate)
Start
Nov 2026
Primary completion
Oct 2028
Study completion Dec 2028
Sponsor
- Lead sponsor
- Viking Therapeutics, Inc.Industry
- Sponsor type
- Industry
- First posted
- Oct 9, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This study is one of two planned Phase 3 studies to support the weight management indication for VK2735 Oral in obese (BMI ≥ 30 kg/m2) or overweight (BMI ≥ 27 kg/m2) adults with Type 2 Diabetes Mellitus.
Conditions
- Weight Loss
Interventions
VK2735 OralDrug
VK2735 Oral is a peptide GLP-1 and GIP dual agonist administered once daily
Placebo ComparatorDrug
Placebo comparator administered orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent change in body weight for participants with type 2 diabetes mellitus receiving VK2735 orally once dailyTime frame: 68 weeks
Locations
19 sites in 1 country. Site status is shown where the registry gives one.
Viking Clinical Site #2020
Tucson, Arizona · Recruiting
Viking Clinical Site #2015
Lake Forest, California · Recruiting
Viking Clinical Site #2059
Ocoee, Florida · Recruiting
Viking Clinical Site #2013
Atlanta, Georgia · Recruiting
Viking Clinical Site #2001
Evansville, Indiana · Recruiting
Viking Clinical Site #2046
Indianapolis, Indiana · Recruiting
Viking Clinical Site #2009
Valparaiso, Indiana · Recruiting
Viking Clinical Site #2004
Richfield, Minnesota · Recruiting
Viking Clinical Site #2029
Jackson, Mississippi · Recruiting
Viking Clinical Site #2028
Springfield, Missouri · Recruiting
Viking Clinical Site #2052
Albuquerque, New Mexico · Recruiting
Viking Clinical Site #2039
Binghamton, New York · Recruiting
Viking Clinical Site #2023
Medford, Oregon · Recruiting
Viking Clinical Site #2002
East Greenwich, Rhode Island · Recruiting
Viking Clinical Site #2044
Charleston, South Carolina · Recruiting
Viking Clinical Site #2030
Hendersonville, Tennessee · Recruiting
Viking Clinical Site #2031
Abilene, Texas · Recruiting
Viking Clinical Site #2011
Seattle, Washington · Recruiting
Viking Clinical Site #2042
Spokane, Washington · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.